{"nctId":"NCT00154102","briefTitle":"Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)","startDateStruct":{"date":"2004-05"},"conditions":["Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer"],"count":1221,"armGroups":[{"label":"Cetuximab Plus FOLFIRI","type":"EXPERIMENTAL","interventionNames":["Drug: Cetuximab","Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)"]},{"label":"FOLFIRI Alone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)"]}],"interventions":[{"name":"Cetuximab","otherNames":[]},{"name":"FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of histologically confirmed adenocarcinoma of the colon or rectum\n* Inoperable metastatic disease\n* Immunohistochemical evidence of epidermal growth factor receptor expression in tumor tissue\n* Presence of at least 1 bi-dimensionally measurable index lesion\n\nExclusion Criteria:\n\n* Previous irinotecan-based chemotherapy\n* Previous chemotherapy for colorectal cancer except adjuvant treatment if terminated more than 6 months before the start of study treatment\n* Radiotherapy, surgery (excluding prior diagnostic biopsy) or any investigational drug in the 30 days before the start of study treatment\n* Brain metastasis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments","description":"Duration from randomization until radiological progression (based on modified World Health Organisation (WHO) criteria) or death due to any cause.\n\nOnly deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":null},{"groupId":"OG001","value":"8.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Progression-free Survival Time (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population) - Independent Review Committee (IRC) Assessments","description":"Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause.\n\nOnly deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":null},{"groupId":"OG001","value":"8.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Progression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments","description":"Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause.\n\nOnly deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival Time (OS)","description":"Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.9","spread":null},{"groupId":"OG001","value":"18.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival Time (KRAS Wild-Type Population)","description":"Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival Time (KRAS Mutant Population)","description":"Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":null},{"groupId":"OG001","value":"16.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Overall Response Rate - Independent Review Committee (IRC) Assessments","description":"The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.9","spread":null},{"groupId":"OG001","value":"38.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Overall Response Rate (KRAS Wild-Type Population) - Independent Review Committee (IRC) Assessments","description":"The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.3","spread":null},{"groupId":"OG001","value":"39.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Overall Response Rate (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments","description":"The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"36.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate - Independent Review Committee (IRC) Assessments","description":"The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments (based on modified WHO criteria).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.3","spread":null},{"groupId":"OG001","value":"85.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response - Independent Review Committee (IRC) Assessments","description":"Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).\n\nPatients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With No Residual Tumor After Metastatic Surgery","description":"Participants with no residual tumor after on-study surgery for metastases","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status","description":"Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.88","spread":"1.185"},{"groupId":"OG001","value":"60.33","spread":"1.155"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.02","spread":"1.187"},{"groupId":"OG001","value":"61.83","spread":"1.176"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.77","spread":"1.276"},{"groupId":"OG001","value":"63.29","spread":"1.249"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.83","spread":"1.368"},{"groupId":"OG001","value":"64.06","spread":"1.364"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.68","spread":"1.590"},{"groupId":"OG001","value":"65.07","spread":"1.612"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.43","spread":"1.835"},{"groupId":"OG001","value":"64.02","spread":"1.991"}]}]}]},{"type":"SECONDARY","title":"Quality of Life Assessment (EORTC QLQ-C30) Social Functioning","description":"Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.21","spread":"1.426"},{"groupId":"OG001","value":"77.28","spread":"1.395"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.14","spread":"1.430"},{"groupId":"OG001","value":"76.71","spread":"1.415"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.72","spread":"1.533"},{"groupId":"OG001","value":"76.67","spread":"1.498"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.31","spread":"1.644"},{"groupId":"OG001","value":"77.98","spread":"1.633"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.04","spread":"1.903"},{"groupId":"OG001","value":"75.64","spread":"1.933"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.58","spread":"2.198"},{"groupId":"OG001","value":"78.07","spread":"2.388"}]}]}]},{"type":"SECONDARY","title":"Safety - Number of Patients Experiencing Any Adverse Event","description":"Please refer to Adverse Events section for further details","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"599","spread":null},{"groupId":"OG001","value":"597","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":263,"n":600},"commonTop":["DIARRHOEA","NAUSEA","NEUTROPENIA","ALOPECIA","VOMITING"]}}}